Monday, February 07, 2005

More Vioxx News for Merck

In an unfortunate double whammy, Merck recieved news that a formal SEC investigation will take place on the way that Merck handled the Vioxx recall. Not only could Merck have lawsuits over the Vioxx recall, but now they can have lawsuits by investors of Merck. To add insult to injury, Merck also found out that their patent exclusivity of the drug Fosamax will end a decade sooner than they had expected.


Post a Comment

<< Home